Literature DB >> 21478771

N-of-1 trials in the medical literature: a systematic review.

Nicole B Gabler1, Naihua Duan, Sunita Vohra, Richard L Kravitz.   

Abstract

BACKGROUND: N-of-1 trials (multiple crossover studies conducted in single individuals) may be ideal for determining individual treatment effects and as a tool to estimate heterogeneity of treatment effects (HTE) in a population. However, comprehensive data on n-of-1 trial methodology and analysis is lacking. We performed this study to describe n-of-1 trial characteristics, examine treatment changes resulting from n-of-1 trial participation, and to determine if trial reporting is adequate for estimating HTE.
METHODS: We undertook a systematic review of n-of-1 trials published between 1985 and December 2010. Included trials were those having individual treatment episodes as the unit of randomization and reporting individual-specific treatment effects. We abstracted trial characteristics, treatment change information, and analytic methods.
RESULTS: We included 108 trials reporting on 2154 participants. Approximately half (49%) of the trials used a statistical cutoff to determine a superior treatment, whereas the remainder used a graphical comparison (25%) or a clinical significance cutoff (20%). Sixty-seven trials, reporting on 488 people, provided treatment change information: 54% of participants had subsequent treatment decisions consistent with the results of the trial, 8% had decisions inconsistent with trial results, and 38% had ambiguous results. Less than half of the trials (45%) reported adequate information to facilitate the calculation of HTE.
CONCLUSION: N-of-1 trials are a useful tool for enhancing therapeutic precision in a range of conditions and should be conducted more often. To facilitate future meta-analysis, and the estimation of HTE, researchers reporting n-of-1 trial results should clearly describe individual data.

Entities:  

Mesh:

Year:  2011        PMID: 21478771     DOI: 10.1097/MLR.0b013e318215d90d

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  64 in total

1.  The landscape of comparative effectiveness research in rheumatology.

Authors:  Esi Morgan DeWitt; Hermine I Brunner
Journal:  Nat Rev Rheumatol       Date:  2013-09-24       Impact factor: 20.543

2.  Patient preferences for personalized (N-of-1) trials: a conjoint analysis.

Authors:  Nathalie Moise; Dallas Wood; Ying Kuen K Cheung; Naihua Duan; Tara St Onge; Joan Duer-Hefele; Tiffany Pu; Karina W Davidson; Ian M Kronish
Journal:  J Clin Epidemiol       Date:  2018-05-30       Impact factor: 6.437

3.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

4.  N-of-1 Trials in Hypertension Are Feasible, but Are They Worthwhile?

Authors:  Richard L Kravitz
Journal:  J Gen Intern Med       Date:  2019-06       Impact factor: 5.128

Review 5.  The Importance and Challenges of Dietary Intervention Trials for Inflammatory Bowel Disease.

Authors:  James D Lewis; Lindsey Albenberg; Dale Lee; Mario Kratz; Klaus Gottlieb; Walter Reinisch
Journal:  Inflamm Bowel Dis       Date:  2017-02       Impact factor: 5.325

Review 6.  Recent highlights of Chinese medicine for advanced lung cancer.

Authors:  Xi-Ran He; Shu-Yan Han; Ping-Ping Li
Journal:  Chin J Integr Med       Date:  2016-12-27       Impact factor: 1.978

7.  Intentional rechallenge and the clinical management of drug-related problems.

Authors:  Ronald Meyboom
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

Review 8.  Drugs for chronic pain in children: a commentary on clinical practice and the absence of evidence.

Authors:  Marie-Claude Grégoire; G Allen Finley
Journal:  Pain Res Manag       Date:  2013 Jan-Feb       Impact factor: 3.037

Review 9.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

10.  Tumour heterogeneity in the clinic.

Authors:  Philippe L Bedard; Aaron R Hansen; Mark J Ratain; Lillian L Siu
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.